Pharmacia/Celltech Anti-TNF Antibody Deal Includes $50 Mil. Up Front
Executive Summary
Pharmacia is paying $50 mil. up front for a chance to broaden its participation in the arthritis market to include Celltech's anti-TNF antibody CDP 870.
You may also be interested in...
Pharmacia R&D Head Ando Leaves For Celltech; Will Still Work With Pfizer
Pharmacia R&D President Goran Ando, MD, will move to the other side of a partnership between Pharmacia and Celltech for the Phase III rheumatoid arthritis agent CDP-870 as Celltech CEO
Pharmacia R&D Head Ando Leaves For Celltech; Will Still Work With Pfizer
Pharmacia R&D President Goran Ando, MD, will move to the other side of a partnership between Pharmacia and Celltech for the Phase III rheumatoid arthritis agent CDP-870 as Celltech CEO
Pharmacia TNF-Inhibitor’s Monthly Dosing Could Offer Marketing Advantage
Pharmacia's experimental tumor necrosis factor inhibitor CDP-870 could gain a competitive advantage through a once-monthly dosing schedule